Veloxis Pharmaceuticals A/S Promotes John Weinberg To Chief Operating Officer

HORSHOLM, Denmark, March 6, 2014 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that John Weinberg, M.D., currently chief commercial officer of Veloxis, has been promoted to chief operating officer.

• Dr. Weinberg, who is currently responsible for the commercial launch of Envarsus® in the U.S., if approved by the Food and Drug Administration (FDA), will expand his role at the company to include additional operational responsibilities.
• Dr. Weinberg joined Veloxis in 2010. Prior to joining Veloxis, Dr. Weinberg was Business Franchise Head at Novartis Pharmaceuticals Corporation in the transplant and infectious disease business unit. In this capacity, he successfully managed and grew the U.S. transplant business.

Dr. Weinberg said, "We are now developing our commercial plans for launching Envarsus^® in the U.S. market. As chief operating officer, I look forward to ensuring a successful introduction of Envarsus^® to transplant recipients, not only in the U.S, but worldwide."

Bill Polvino, M.D., chief executive officer of Veloxis said, "The U.S. launch of Envarsus^® is of great significance to the company as it is our first product for which we will manage its commercialization. John's experience in the organ transplant field will provide us the expertise to position us for success in the U.S. and worldwide. I want to personally congratulate John on his promotion."

For more information, please contact:
Veloxis Pharmaceuticals A/S
John Weinberg, M.D.
EVP & Chief Operating Officer
Phone: +1 732 321 3208
Email: jdw@veloxis.com

About Envarsus^® (formerly LCP-Tacro) and tacrolimus
Tacrolimus is a leading immunosuppression drug used for the prevention of transplant allograft rejection after organ transplantation. Envarsus^® is an investigational drug that is being developed as a once daily tablet version of tacrolimus, with improved bioavailability, consistent pharmacokinetic performance and reduced peak to trough variability when compared to currently approved tacrolimus products. Transplant patients need to maintain a minimum blood level of tacrolimus for the prevention of transplant allograft rejection, but excessive levels may increase the risk of serious side effects such as nephrotoxicity, tremor, diabetes, high blood pressure, and opportunistic infections. Therefore, tacrolimus levels need to be managed carefully, and transplant patients are typically obliged to make frequent visits to the hospital for monitoring and dose adjustments after receiving a new organ.

About Veloxis Pharmaceuticals
Based in Horsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. The company's lead product candidate is Envarsus^® for immunosuppression, specifically organ transplantation. Veloxis' unique, patented delivery technology, MeltDose^®, can improve absorption and bioavailability at low scale up costs. Veloxis has a lipid lowering product, Fenoglide^®, currently on the U.S. market that is commercialized through partner Santarus, Inc. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.
For further information, please visit www.veloxis.com.

SOURCE Veloxis Pharmaceuticals A/S